Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETOP 21-21 BOUNCE
2022-502467-38-00Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Feb 2024
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Brigatinib consolidation, Durvalumab consolidation and Observation (3 arms). Primary endpoint: Progression-free survival. Started Feb 2024; status: completed.
02
Drugs
brigatinibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-502467-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502467-38-00.